Treatment of left-sided prosthetic valve endocarditis by suppressive antibiotic therapy: A retrospective monocentric real-world study - 03/09/25
, M. Boisson a, D. Rhem b, M. Korabi c, A. Behouche b, M. Blanc d, O. Chavanon aHighlights |
• | Prosthetic valve endocarditis (PVE) remains a therapeutic challenge, in some cases requiring high-risk surgery. |
• | Suppressive antibiotic therapy (SAT) improve survival in case of unremoved infected extracardiac materials. |
• | In our recent PVE management, SAT yielded overall survival that was higher than predicted. The relapse rate within the first year was low. |
• | A conservative approach with SAT could be a feasible in PVE strategy in selected patients for whom surgical risk is too high. |
Abstract |
Objectives |
Prosthetic valve endocarditis has a poor prognosis, with high risks of relapse complicating management. Suppressive antibiotic therapy is increasingly considered as a means of treatment for infected devices that cannot be removed. We compared i) early mortality and ii) one-year overall and relapse-free survival between different strategies in real-world management of prosthetic valve endocarditis, one of them being suppressive antibiotic therapy.
Patients and methods |
This single-center retrospective study included patients with aortic or mitral prosthetic valve endocarditis managed between 2019 and 2021. Each strategy was patient-centered and decided on by a multidisciplinary team. At first, we divided the population between surgically and conservatively managed patients. Initial intravenous antibiotic therapy lasted at least six weeks, and we compared early mortality having occurred prior to its completion. At a later stage, we divided the conservatively managed survivors between those who received suppressive antibiotic therapy and those who did not, and we compared survival and relapse rates during the first year subsequent to adaptation of each strategy.
Results |
Seventy-five patients were included. Biological prostheses (33 %) for aortic valve replacement (95 %) predominated. The 17 (22.3 %) surgically managed patients were younger. Among the 58 conservatively managed patients, 42 had a theoretical indication for surgery. Eleven (14.6 %) patients died before having completed their course of intravenous antibiotic therapy, with no difference between surgical and conservative strategies (17.6 % vs. 13.8 %, p = 0.7043). Out of the 50 conservatively managed survivors, 35 received suppressive antibiotic therapy. Overall one-year survival was 73.9 % [64.1–85.2] and did not differ from one strategy to the next. Only six relapses occurred within the first year, including one (7.1 %) in surgically managed survivors and two (5.6 %) among the conservatively managed survivors receiving suppressive antibiotic therapy (5.6 %).
Conclusions |
While surgery remains the gold standard for prosthetic valve endocarditis, especially in complicated cases, suppressive antibiotic therapy appeared suitable for selected patients for whom the surgical option seemed excessively risky.
Le texte complet de cet article est disponible en PDF.Keywords : Prosthetic valve endocarditis, Suppressive antibiotic therapy, Survival
Plan
Vol 55 - N° 6
Article 105112- septembre 2025 Retour au numéro
Article précédent
- New epidemio-clinical insights into cutaneous leishmaniasis caused by Leishmania infantum in Casablanca, Morocco
- Bouchra Baghad, Zineb Mouhsine, Fatima Zahra Chekairi, Bouchra Amine, Imane El Idrissi Saik, Kaltoum Lemkhayar, Meryem Lemrani, Maha Soussi Abdallaoui, Soumiya Chiheb, Myriam Riyad
- Optimizing Outpatient Parenteral Antimicrobial Therapy (OPAT): A survey of community nurses’ practices in France
- S. Raux, A. Communaux, J.P. Talarmin, L. Khatchatourian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?